



Press Release

Labomar Group: H1 consolidated revenues of Euro 41.8 million (+36.9%)

Chief Executive Officer Bertin: *"These results create confidence for the rest of the year."*

Istrana (TV), July 21, 2022 — Labomar SpA (Ticker: LBM), an Italian-based international nutraceutical enterprise and listed on the Euronext Growth Milan market, announces H1 2022 consolidated revenues of approx. Euro 41.8 million, up 36.9% on H1 2021 (Euro 30.5 million).

Consolidated revenues include - in addition to Labomar Spa and Entreprises ImportFab Inc. - the companies acquired in H2 2021, i.e. the Welcare Group and Labiotre Srl. On a like-for-like basis with the first half of the previous year, consolidated revenues totalled Euro 34.1 million, up nearly 12% on 2021. This growth is particularly supported by the parent company, which saw a "probiotics and cough&cold" product category sales recovery, which had been particularly impacted in 2021 by the COVID-19 pandemic. The main international key accounts also saw growth and the portfolio of new products launched in the past 12 months expanded.

"I am greatly satisfied with the performance for this first half of the year, with double-digit sales growth, despite an unfavourable socio-economic environment, with the pandemic still not completely behind us," outlined Labomar founder and Chief Executive Officer Walter Bertin. *"These results - to which all the Group companies have contributed - not only confirm the market guidance, but also give rise to confidence for a strong second half to the year. The orders to-date and the agreements signed with both new and consolidated customers - most recently with Noventure, as communicated in recent days - give rise to confidence and optimism. It also confirms the trusting relationships established over time with our partners, which develop further our constant commitment to research and development and also our sustainability approach, to which customers and suppliers are also paying increasing attention."*

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020.

Labomar S.p.a.

Via N. Sauro, 35/1 - 31036 Istrana (TV)
C.Fisc. e P.Iva IT03412720264 - REA TV-269752 - Cap. Soc.€ 1.848.404,30 i.v.

tel: 0422 7312 - fax: 0422 836547
labomar@pec.it - contact@labomar.com
www.labomar.com



Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of medical devices for skincare, with its registered office in Orvieto. LaboVar Srl was also established - 51% owned by Labomar - for the sale of nutraceutical products on an e-commerce platform on the Chinese market.

Labomar then acquired full control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For further information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Investor Relations Labomar

Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com

Mara Di Giorgio - +39.335.7737417 - mara@twin.services

Euronext Growth Advisor

Banca Mediolanum - +39 02 9049 2525 - ecm@mediolanum.it